Media Coverage · January 4, 2018
Acticor Biotech réalise une augmentation de capital de 1,7M€ – Biotech Info [FR]
January 2018. Acticor Biotech, société de biotechnologie spécialisée dans la phase aigüe des maladies thromboemboliques dont l’accident vasculaire cérébral (AVC) et l’embolie pulmonaire, annonce aujourd’hui la réalisation d’une augmentation de capital de 1,7 M€.
Download full text article (PDF, French)
Read next in 'Media Coverage'
- Novel antiplatelet could circumvent bleeding risk for stroke patients
- Experimental antiplatelet compound for acute stroke shows promise
- New drug to prevent clots clears safety hurdle
- New blood thinner may prevent stroke, without risk for bleeding
- Acticor's blood thinner cuts hemorrhage risk in human study, could offer hope for acute stroke